01 / 05
1,000 Bits of Good News You May Have Missed in 2023

Blog Post | Human Development

1,000 Bits of Good News You May Have Missed in 2023

A necessary balance to the torrent of negativity.

Reading the news can leave you depressed and misinformed. It’s partisan, shallow, and, above all, hopelessly negative. As Steven Pinker from Harvard University quipped, “The news is a nonrandom sample of the worst events happening on the planet on a given day.”

So, why does Human Progress feature so many news items? And why did I compile them in this giant list? Here are a few reasons:

  • Negative headlines get more clicks. Promoting positive stories provides a necessary balance to the torrent of negativity.
  • Statistics are vital to a proper understanding of the world, but many find anecdotes more compelling.
  • Many people acknowledge humanity’s progress compared to the past but remain unreasonably pessimistic about the present—not to mention the future. Positive news can help improve their state of mind.
  • We have agency to make the world better. It is appropriate to recognize and be grateful for those who do.

Below is a nonrandom sample (n = ~1000) of positive news we collected this year, separated by topic area. Please scroll, skim, and click. Or—to be even more enlightened—read this blog post and then look through our collection of long-term trends and datasets.

Agriculture

Aquaculture

Farming robots and drones

Food abundance

Genetic modification

Indoor farming

Lab-grown produce

Pollination

Other innovations

Conservation and Biodiversity

Big cats

Birds

Turtles

Whales

Other comebacks

Forests

Reefs

Rivers and lakes

Surveillance and discovery

Rewilding and conservation

De-extinction

Culture and tolerance

Gender equality

General wellbeing

LGBT

Treatment of animals

Energy and natural Resources

Fission

Fusion

Fossil fuels

Other energy

Recycling and resource efficiency

Resource abundance

Environment and pollution

Climate change

Disaster resilience

Air pollution

Water pollution

Growth and development

Education

Economic growth

Housing and urbanization

Labor and employment

Health

Cancer

Disability and assistive technology

Dementia and Alzheimer’s

Diabetes

Heart disease and stroke

Other non-communicable diseases

HIV/AIDS

Malaria

Other communicable diseases

Maternal care

Fertility and birth control

Mental health and addiction

Weight and nutrition

Longevity and mortality 

Surgery and emergency medicine

Measurement and imaging

Health systems

Other innovations

Freedom

    Technology 

    Artificial intelligence

    Communications

    Computing

    Construction and manufacturing

    Drones

    Robotics and automation

    Autonomous vehicles

    Transportation

    Other innovations

    Science

    AI in science

    Biology

    Chemistry and materials

      Physics

      Space

      Violence

      Crime

      War

      Gavi | Vaccination

      Global Mpox Stockpile to Speed Vaccine Access

      “A new global mpox vaccine stockpile is set to begin operations later this month, creating a long-term mechanism to help ensure that countries facing mpox outbreaks have rapid and equitable access to vaccines.

      Like existing global emergency stockpiles for yellow fever, meningitis, Ebola and cholera vaccines, the mpox stockpile will be available to any country that needs it. However, because supplies are limited and must be distributed equitably, it is designed primarily for emergency outbreak response.

      Countries eligible for Gavi support receive stockpiled vaccines free of charge. Wealthier countries can access the stockpile just as quickly, but these countries must subsequently reimburse the cost of the vaccines.”

      From Gavi.

      World Health Organization | Vaccination

      Global Childhood Vaccination Rises but Trails 2019

      “In 2025, 90% of infants globally – or nearly 116 million – received at least one dose of a diphtheria, tetanus and pertussis (DTP) vaccine, and 85% – or 110 million – completed the full three-dose series, according to the annual WHO-UNICEF Estimates of National Immunization Coverage (WUENIC) released today.

      While both indicators rose by one percentage point from the previous year, global coverage remains one point below 2019 levels – hovering within the same narrow range since 2009.

      According to the data, an estimated 13.5 million 'zero-dose' children did not receive a single vaccine in their first year during 2025. While these represent nearly 750 000 fewer children than the previous year, progress is offset by a rising number of children who start the schedule and do not complete it. Most of these children live in countries where national immunization programmes receive support from Gavi, the Vaccine Alliance.”

      From World Health Organization.

      BBC | Vaccination

      Fridge-Free Vaccine Successfully Tested in Humans

      “Vaccines that do not need to be kept cool in a fridge have been successfully trialled in patients for the first time, say UK scientists.

      Currently, most vaccines need to be refrigerated or frozen – but around half are wasted each year, mainly because they become unusable after getting too hot or too cold.

      In the trial, which involved 60 volunteers, company Stablepharma converted a liquid tetanus-diphtheria vaccine into a 'fridge-free' version by keeping it as a dry powder for a year at room temperature before mixing it with water and injecting it.”

      From BBC.

      Wall Street Journal | Vaccination

      FDA Approves First mRNA Flu Vaccine

      “The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine Wednesday for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February.

      The vaccine, called mFlusiva, uses the same messenger RNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall…

      Traditional flu shots are grown in chicken eggs, a process that takes about six months and forces manufacturers to guess months in advance which strains will circulate. Moderna’s mRNA shot can be made in as little as two to three months, meaning it could better match the actual virus once flu season arrives…

      In a study of more than 40,000 adults, mFlusiva cut the risk of flu by 26.6% compared with a standard-dose vaccine. That reduction was 47.9% against flu severe enough to send patients to the hospital or urgent care.”

      From Wall Street Journal.